The bone-marrow niche — the address a blood stem cell lives at, which 26 entries in this graph invoke and none had defined
also called haematopoietic stem cell niche · HSC niche · bone marrow microenvironment · BMM
The bone marrow is not a bag of loose cells: it is an organ with addresses, and a blood stem cell only behaves like a stem cell when it sits at the right one, held there by signals from the cells around it. That address is called the niche, and leukaemia cells move into it, shelter there from chemotherapy, and remodel it so it suits them better than it suits normal blood.
The same thing, for a scientist
The haematopoietic stem cell (HSC) niche is the anatomically and molecularly defined microenvironment inside bone marrow that maintains HSC self-renewal, quiescence and retention. Four decades of work converged on a small set of cellular constituents: **CXCL12-abundant reticular (CAR)/LEPR-positive perivascular stromal cells**, the dominant source of CXCL12 and SCF, whose loss depletes HSCs [E1][E2]; **NG2-positive periarteriolar pericytes**, which specifically maintain quiescence, with cycling HSCs redistributing to LEPR-positive perisinusoidal sites [E3]; **Nestin-positive mesenchymal stem cells**, spatially paired with HSCs and with adrenergic nerve fibres [E4]; **osteoblastic cells at the endosteum**, the first proposed niche [E5]; **sinusoidal endothelium**; **megakaryocytes**, covered in `cell-type-megakaryocyte`; **adipocytes**, predominantly negative regulators; and **sympathetic nerve fibres**, which impose a circadian rhythm on CXCL12 and thus on HSC egress [E6]. Direct two-photon phosphorescence measurement in live mice showed marrow pO2 is low everywhere (<32 mmHg) and **lowest in deep peri-sinusoidal regions (~9.9 mmHg, 1.3 percent), with the endosteum *less* hypoxic** because it is perfused by small arteries [E7] — which inverts the textbook hypoxic-endosteal-niche picture. Every one of these components has a documented interaction with KMT2A-rearranged leukaemia, and each is written as a separate entry in this beat.
Layman first: what the niche is, where it is, and what it does for a healthy blood cell
Every drop of blood in a child's body is replaced constantly — red cells last about four months, some white cells only hours. All of it is made in the bone marrow, the soft tissue inside the hollow centre of bones, by a very small number of blood stem cells. A single one of them can make every kind of blood cell, and can make copies of itself.
The trouble with a stem cell is that it is useless if it does either job too enthusiastically. Divide constantly and it exhausts itself and the supply fails; never divide and nothing gets made. Something has to tell it which to do and when. That something is not inside the cell. It is the place the cell is sitting in.
A niche, in ecology, is the slot an organism occupies in its environment. A stem-cell niche is the same idea shrunk to a few cell-widths: a specific spot in the marrow, surrounded by specific neighbouring cells, releasing specific molecules the stem cell can feel. Sit in the niche and you are held still, fed and protected. Leave it and you start dividing, or you wash out into the bloodstream and leave the marrow altogether.
Where is it? Bone marrow is threaded with blood vessels. Small arteries (arterioles) bring blood in under pressure; the marrow drains through wide, leaky, slow-flowing vessels called sinusoids. Wrapped around both are stromal cells — the supporting, non-blood cells of a tissue. At the edge of the marrow cavity, lining the inner surface of the bone itself, is the endosteum, a layer of bone-building cells (osteoblasts). Most blood stem cells sit against a vessel wall, touching a stromal cell; some sit near the bone surface. Running alongside the arterioles are nerve fibres of the sympathetic nervous system — the fight-or-flight system — which turn the niche's signals up and down on a daily clock.
What does it do for the cell? Four things, each with a named molecule:
- Holds it there. Stromal cells pour out a chemical called CXCL12 (also called SDF-1). Stem cells carry the matching receiver, CXCR4. CXCL12 is a homing beacon; block CXCR4 and stem cells wash out of the marrow into the blood within hours. This is not a laboratory curiosity — it is how the drug plerixafor is used in clinics to collect stem cells from donors.
- Keeps it alive. Stromal and endothelial cells make stem cell factor (SCF/KITL), without which stem cells die 2.
- Keeps it still. Signals from periarteriolar cells 3, from megakaryocytes and from TGF-beta hold the cell in a resting state (see
cell-state-quiescence). A resting cell is a protected cell: nearly every leukaemia drug works best on cells that are dividing. - Sets a rhythm. Sympathetic nerves lower CXCL12 at a fixed time each day, releasing a pulse of stem cells into the circulation 6.
The reason a cancer graph cares is point 3. The same address that protects a healthy stem cell protects a leukaemia cell — and the leukaemia does not merely squat there, it rebuilds the place. That story is in mechanism-leukaemia-remodels-its-own-niche.
The components, and where each one is written up
| component | what it does for a healthy HSC | entry |
|---|---|---|
| CAR / LEPR+ perivascular stromal cell | dominant source of CXCL12 and SCF; retention and maintenance | cell-type-car-cell |
| NG2+ periarteriolar pericyte | enforces quiescence; quiescent HSCs sit specifically at arterioles | cell-type-ng2-periarteriolar-cell |
| Nestin+ mesenchymal stem cell | HSC-maintenance gene expression; paired with nerve fibres | cell-type-nestin-msc |
| osteoblast / endosteum | first-proposed niche; jagged-1/Notch and N-cadherin contacts | cell-type-osteoblast, concept-endosteal-niche |
| sinusoidal endothelial cell | SCF source; the exit door to the blood | cell-type-sinusoidal-endothelial-cell, concept-perivascular-sinusoidal-niche |
| megakaryocyte | CXCL4/TGF-beta1 quiescence, FGF1 expansion after injury | cell-type-megakaryocyte (written cycle 39) |
| adipocyte | predominantly a negative regulator of haematopoiesis | cell-type-bone-marrow-adipocyte |
| sympathetic nerve fibre | circadian control of CXCL12 and HSC egress | cell-type-bone-marrow-sympathetic-nerve |
| oxygen gradient | low everywhere, lowest peri-sinusoidally | concept-marrow-oxygen-gradient |
The granularity rule applies: each of these is one thing and gets one entry. This entry is the map, not a substitute for them.
What this entry deliberately does not claim
Almost all of the cellular anatomy above is mouse work, built on conditional knockouts and reporter alleles with no human equivalent. The human marrow niche has been described mainly by imaging and single-cell transcriptomics, not by functional deletion, and the correspondence between mouse Lepr+/Nestin+/NG2+ populations and human stromal subsets is an active argument rather than a settled mapping.
Second, the field has repeatedly overturned itself. The endosteal/osteoblastic niche was the consensus from 2003 5; by 2012 conditional deletion showed that SCF from osteoblasts is dispensable while SCF from endothelium and LEPR+ perivascular cells is essential 2. Treat 'the niche' as a set of experimentally separable activities, not as a place with a fixed address.
Third, this entry claims nothing about infants. Every functional study cited is in adult mice. Since the disease of interest here presents at a median age of a few months, and since the developmental stage of the niche demonstrably changes the lineage of MLL-rearranged leukaemia (mechanism-niche-developmental-stage-sets-leukaemia-lineage), assuming the adult niche describes the infant marrow would be an error this graph should not make.
| definition | The anatomically and molecularly defined bone-marrow microenvironment that maintains haematopoietic stem cell self-renewal, quiescence and retention |
|---|---|
| species caveat | essentially all functional evidence is mouse; the human niche is described by imaging and transcriptomics rather than conditional deletion |
| developmental caveat | all cited functional work is in adult mice; the infant marrow niche is not characterised, and niche developmental stage is known to change MLL-rearranged leukaemia lineage |
anatomical compartments
[ "endosteal / osteoblastic (bone-lining)", "periarteriolar (NG2+ pericytes, small arteries)", "perisinusoidal (LEPR+ / CAR cells, sinusoidal endothelium)" ]
measured oxygen tension
[
{
"region": "bone marrow overall",
"value": 32,
"unit": "mmHg (upper bound)",
"source_evidence": "E7"
},
{
"region": "deep peri-sinusoidal",
"value": 9.9,
"unit": "mmHg (approx 1.3 percent O2)",
"source_evidence": "E7"
},
{
"region": "endosteal",
"value": null,
"unit": "not quantified; reported as LESS hypoxic than peri-sinusoidal",
"source_evidence": "E7"
}
]core molecules
[ "CXCL12 (SDF-1)", "CXCR4", "SCF (KITL)", "KIT", "TGF-beta1", "CXCL4 (PF4)", "jagged-1/NOTCH1", "N-cadherin", "noradrenaline via ADRB2/ADRB3" ]
component entries
[ "cell-type-car-cell", "cell-type-ng2-periarteriolar-cell", "cell-type-nestin-msc", "cell-type-osteoblast", "cell-type-sinusoidal-endothelial-cell", "cell-type-bone-marrow-adipocyte", "cell-type-bone-marrow-sympathetic-nerve", "cell-type-megakaryocyte" ]
- The niche is not a leukaemia-specific structure. Every pharmacological attempt to disrupt it also disrupts the compartment the patient depends on to recover their own counts, which is precisely why plerixafor is used clinically to mobilise normal stem cells rather than to kill leukaemic ones.
- 'Niche protection' is easy to invoke and hard to falsify, and this graph has already rejected it once as a menin-inhibitor resistance mechanism because no primary study supports it in that setting. An entry treating the niche as a general explanation for treatment failure would repeat that error.
- Expanding the osteoblastic niche with PTH reduces CML stem cells but INCREASES MLL-AF9 AML, so niche-directed interventions can be actively harmful in a genotype-specific way.
- What does the infant bone-marrow niche look like? Every functional study cited here is in adult mice, and the disease in this graph presents in the first year of life.
- Are CAR cells, LEPR+ perivascular cells and Nestin+ MSCs three populations, two, or one seen through three reporters? The conditional-deletion results disagree in a way usually blamed on cre drivers rather than biology, which is not a resolution.
- Where is the hypoxic compartment? Direct pO2 measurement says peri-sinusoidal and explicitly not endosteal; the MLL-AF9 metabolic-imaging literature says leukaemia-initiating cells home to a hypoxic endosteal niche. These cannot both be right.
- Does human paediatric marrow contain periarteriolar NG2+ pericytes at all, and can they be identified in a diagnostic trephine biopsy, which is the only human marrow tissue routinely available?
- E1established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.paper
Induced deletion of CXCR4 in adult mice severely reduces HSC numbers and increases sensitivity to myelotoxic injury without impairing expansion of more mature progenitors; most HSCs contact CXCL12-abundant reticular (CAR) cells, which surround sinusoidal endothelial cells or lie near the endosteum, making CXCL12-CXCR4 signalling essential for maintaining the quiescent HSC pool.
Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches · Sugiyama T, Kohara H, Noda M, Nagasawa T · Immunity 2006What this evidence cannot show
Mouse, induced conditional deletion. CAR cells were defined by CXCL12 reporter intensity, a definition later work largely subsumed into the LEPR-positive perivascular population; whether CAR and LEPR+ cells are one population under two names is still argued. Read: abstract only.
Evidence that argues against this (1)
- CXCR4's requirement in leukaemia is not the same requirement as in normal HSCs, and the difference undermines a simple 'CXCL12 holds cells in the niche' reading. A CRISPR screen in syngeneic MLL-AF9 AML found Cxcr4 deletion eradicated leukaemia in vivo WITHOUT impairing homing to the bone marrow, and CXCL12 itself was dispensable for leukaemia development in recipients; loss of CXCR4 signalling caused oxidative stress and differentiation. In this disease CXCR4 can be essential for a reason unrelated to the chemokine gradient that defines the niche. Read: abstract only. Ramakrishnan R et al. 2020
- E2established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.paper
Stem cell factor (SCF/KITL) is expressed primarily by perivascular cells throughout the bone marrow; HSC frequency and function are unaffected when Scf is deleted from haematopoietic cells, osteoblasts or Nestin-cre-expressing cells, but HSCs are depleted when Scf is deleted from endothelial cells or from leptin-receptor-expressing perivascular stromal cells, and most HSCs are lost when it is deleted from both.
Endothelial and perivascular cells maintain haematopoietic stem cells · Ding L, Saunders TL, Enikolopov G, Morrison SJ · Nature 2012What this evidence cannot show
Mouse, Scf-GFP knock-in plus conditional deletion. The negative result for Nestin-cre is contested by the group that defined Nestin+ MSCs, partly on the grounds that Nestin-cre and Nestin-GFP label different populations; this is a live methodological dispute about cre-driver specificity, not a settled refutation. Read: abstract only.
Evidence that argues against this (1)
- Nestin-positive MSCs were reported in the same period to be an essential HSC niche component, with in vivo depletion rapidly reducing marrow HSC content and progenitor homing, and with Nestin+ MSCs containing all bone-marrow CFU-fibroblast activity. The SCF-deletion result places the maintenance factor elsewhere; both cannot be the whole story. Read: abstract only. Mendez-Ferrer S et al. 2010
- E3strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
Whole-mount confocal imaging with computational three-dimensional association analysis shows quiescent HSCs associate specifically with small arterioles preferentially found in endosteal marrow; these arterioles are ensheathed exclusively by rare NG2/CSPG4-positive pericytes distinct from sinusoid-associated LEPR-positive cells; activating the HSC cell cycle redistributes HSCs from NG2+ periarteriolar to LEPR+ perisinusoidal niches, and conditional depletion of NG2+ cells induces HSC cycling and reduces long-term repopulating HSCs.
Arteriolar niches maintain haematopoietic stem cell quiescence · Kunisaki Y, Bruns I, Scheiermann C, Ahmed J, Pinho S, Zhang D, et al. · Nature 2013What this evidence cannot show
Mouse. The core claim is a spatial-statistical association; the causal arm is NG2+ cell depletion, which removes a pericyte population with functions beyond HSC support. 'Preferentially found in endosteal bone marrow' means the arteriolar and endosteal descriptions overlap anatomically, a frequent source of confusion in this literature. Read: abstract only.
Evidence that argues against this (1)
- The assignment of quiescence to the arteriolar niche competes with the finding that megakaryocytes, a haematopoietic rather than stromal cell, sit non-randomly next to HSCs and that their depletion specifically abolishes HSC quiescence. The niche activity 'maintain quiescence' has at least two independent claimants with independent depletion evidence. Read: abstract only. Bruns I et al. 2014
- E4strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
Mesenchymal stem cells identified by Nestin expression constitute an essential HSC niche component: they contain all bone-marrow CFU-fibroblastic activity, are spatially associated with HSCs and with adrenergic nerve fibres, highly express HSC-maintenance genes that are selectively downregulated on enforced mobilization or beta-3 adrenoreceptor activation, and their in vivo depletion rapidly reduces marrow HSC content and progenitor homing.
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche · Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, et al. · Nature 2010What this evidence cannot show
Mouse, Nestin-GFP reporter. Whether Nestin-GFP+ cells are a distinct population or overlap heavily with LEPR+ perivascular cells is unresolved, and cre-driver discrepancies drive much of the disagreement. Read: abstract only.
Evidence that argues against this (1)
- Conditional deletion of Scf from Nestin-cre-expressing cells had no effect on HSC frequency or function, while deletion from LEPR+ perivascular cells or endothelium depleted HSCs, placing the essential maintenance factor outside the Nestin-cre compartment. Read: abstract only. Ding L et al. 2012
- E5established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.paper
Osteoblastic cells are a regulatory component of the HSC niche in vivo: mice engineered to express an activated PTH/PTHrP receptor in osteoblasts have increased osteoblast numbers, high jagged-1, increased HSC numbers with in vivo Notch1 activation, and PTH injection into wild-type mice increases stem-cell number and markedly improves survival after bone marrow transplantation.
Osteoblastic cells regulate the haematopoietic stem cell niche · Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, et al. · Nature 2003What this evidence cannot show
Mouse, gain-of-function genetics plus pharmacology. Later conditional-deletion work showed osteoblast-derived SCF is dispensable for HSC maintenance, so this paper establishes that osteoblasts CAN regulate the niche, not that they are required for it. Read: abstract only.
Evidence that argues against this (1)
- The same osteoblastic manipulation has opposite effects in different leukaemias. Osteoblast-specific activation of the PTH receptor ATTENUATED BCR-ABL1-driven CML-like disease (a 15-fold decrease in LSCs) but ENHANCED MLL-AF9-driven AML in mouse transplantation models, attributed to opposing effects of increased niche TGF-beta1. Expanding the osteoblastic niche is therefore not generically protective, and in the genotype this graph is about it would be expected to make things worse. Read: abstract only. Krause DS et al. 2013
- E6strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
Circulating HSCs and progenitors oscillate on a circadian rhythm in antiphase with bone-marrow Cxcl12 expression; the cyclical release and the Cxcl12 oscillation are driven by core clock genes acting through circadian noradrenaline secretion from sympathetic nerves innervating the marrow, transmitted to stromal cells by the beta-3 adrenergic receptor, reducing nuclear Sp1 and rapidly downregulating Cxcl12.
Haematopoietic stem cell release is regulated by circadian oscillations · Mendez-Ferrer S, Lucas D, Battista M, Frenette PS · Nature 2008What this evidence cannot show
Mouse; mice are nocturnal, so the phase does not transfer to human clock time without reversal. The receptor here is beta-3; in leukaemia the pro-leukaemic adrenergic signal was mapped to beta-2 and explicitly not beta-3, so the normal and malignant adrenergic circuits are not the same circuit. Read: abstract only.
Evidence that argues against this (1)
- In an MLL-AF9 AML model the adrenergic signalling that promotes leukaemogenesis was transduced by the beta-2, not the beta-3, adrenergic receptor on stromal cells, and the direction of the biology is inverted: leukaemia destroys sympathetic fibres rather than exploiting their normal rhythm. A therapeutic inference drawn from circadian beta-3 physiology would be aimed at the wrong receptor. Read: abstract only. Hanoun M et al. 2014
- E7strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
Direct in vivo two-photon phosphorescence lifetime measurement of local oxygen tension in live mouse bone marrow gives absolute pO2 below 32 mmHg throughout despite very high vascular density, with the lowest values (about 9.9 mmHg, 1.3 percent) in deep peri-sinusoidal regions and the endosteal region LESS hypoxic because it is perfused by small, often Nestin-positive arteries; these values change markedly after radiation and chemotherapy.
Direct measurement of local oxygen concentration in the bone marrow of live animals · Spencer JA, Ferraro F, Roussakis E, Klein A, Wu J, Runnels JM, et al. · Nature 2014What this evidence cannot show
Mouse calvarium, which is thin and accessible and may not represent long-bone or vertebral marrow where most human haematopoiesis occurs. The measurement is of local pO2, not of intracellular hypoxic signalling; cells can mount a HIF response at oxygen tensions this method would score as unremarkable. Read: abstract only.
Evidence that argues against this (1)
- Metabolic imaging in an MLL-AF9 model reports that the most leukemogenic, glycolytic SoNar-high leukaemia-initiating cells home to and locate in what its authors describe as the HYPOXIC ENDOSTEAL niche, which is the opposite spatial assignment of oxygen to the one obtained by direct pO2 measurement. At least one of the two descriptions of where the low-oxygen compartment is must be wrong, and the discrepancy is unresolved. Read: abstract only. Hao X et al. 2019
the marrow oxygen gradient is the physiological source of the state; CNS-derived leukaemia-propagating cells are enriched for hypoxia pathways relative to marrow-derived ones
the niche imposes and reverses the G0 state; dormancy in xenografts is reversible on removal from the niche
maintains HSC self-renewal, retention and quiescence
haematopoietic niche cell; CXCL4/TGF-beta1 at homeostasis, FGF1 after chemotherapy
- related to →Where KMT2A-rearranged leukemia physically sits — marrow niche, CNS, blood, liver/spleen and skin
defines the marrow compartment that entry records KMT2A-r blasts occupying
MLL-AF9 AML disrupts sympathetic fibres and swaps NG2+ periarteriolar cells for osteoblast-primed MSPCs
dominant CXCL12 and SCF source of the perivascular niche
- ← part ofNestin+ mesenchymal stem cell — the niche cell that MLL-AF9 leukaemia wakes up and then loses
perivascular mesenchymal niche cell paired with HSCs and nerve fibres
periarteriolar compartment of the niche
- ← part ofOsteoblast — the bone-building niche cell whose expansion suppresses CML and makes MLL-AF9 AML worse
endosteal compartment; first-proposed niche cell
vascular compartment; required SCF source and the exit route to blood
predominantly negative regulator of the marrow microenvironment
circadian noradrenaline sets marrow CXCL12 and HSC egress
bone-lining compartment of the niche
vascular compartment; where the conditional-deletion evidence for HSC maintenance sits
the retention axis of the niche
the niche's developmental stage is the variable; adult stromal Ccl5 suppresses B-lymphoid differentiation
protection is conferred by direct contact with stromal, endothelial and mesenchymal niche cells and ECM
the oxygen dimension of the niche; lowest pO2 is peri-sinusoidal, not endosteal
the integrin adhesion arm of the niche interaction, alongside the CXCL12-CXCR4 chemokine arm
the enumeration behind this beat's entry list, with both halves of every intersection counted
the shared on-target liability of every intervention in this beat
secreted retention factor of the marrow niche
adhesion arm of the niche, alongside the CXCL12-CXCR4 chemokine arm
stromal/endothelial counter-receptor of the niche adhesion arm
one of the two canonical HSC-maintenance factors of the niche, with CXCL12
census of how much niche biology is measured in this disease rather than borrowed